SCHEMBL4120109

SCHEMBL4120109

CCOC(=O)c1c(C)nn2c(N3CCSCC3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.44
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 3/20 0.42
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GRM6 O15303 1/20 0.41
TSHR P16473 1/20 0.39
MAPK1 P28482 2/20 0.38
P2RY12 Q9H244 2/20 0.38
RAB9A P51151 2/20 0.38
PKM P14618 1/20 0.38
ATM Q13315 1/20 0.38
ALOX5 P09917 2/20 0.38
PDE4D Q08499 1/20 0.38
PDE2A O00408 1/20 0.37
PDE10A Q9Y233 1/20 0.37
GPR119 Q8TDV5 1/20 0.37
BCL2 P10415 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120366 0.84 PDE4B (0.52) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL4109766 0.78 KDM4E (0.50) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL4108305 0.78 PDE4B (0.44) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL4114389 0.77 ALDH1A1 (0.47) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL4129151 0.75 KDM4E (0.49) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL2087300 0.75 PDE4B (0.42) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL2087297 0.75 GPR119 (0.46) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL2086791 0.72 KDM4E (0.46) KDM4EALDH1A1HPGDMAPTL3MBTL1
SCHEMBL4121602 0.72 KDM4E (0.46) PDE4BKDM4EALDH1A1HPGDMAPT
SCHEMBL4120972 0.71 KDM4E (0.44) PDE4BKDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD PDE4B 1938/4885KDM4E 2108/4885ALDH1A1 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.